ThirdEye Announces $100M AI/MR Partnership with Japan's OmGeneum to Radically Improve Medical Industry
As a part of this contract, ThirdEye will work with OmGeneum who has developed a next-generation technology to modulate targeted tissue, organs, or cell regeneration, to improve regenerative (stem cell) medicine treatments for neurological diseases, disorders and dysfunctions.
- As a part of this contract, ThirdEye will work with OmGeneum who has developed a next-generation technology to modulate targeted tissue, organs, or cell regeneration, to improve regenerative (stem cell) medicine treatments for neurological diseases, disorders and dysfunctions.
- ThirdEye's AI/MR software can be used for a wide variety of medical use cases ranging from aiding the vision impaired, Alzheimer's, remote surgery, surgical 3D overlay, health AI analysis & first responder assistance.
- "We are excited about this long-term partnership in the intersection of artificial intelligence, mixed reality and healthcare.
- This award follows prior successful AI/MR deployments by ThirdEye to US Defense and Healthcare customers.